Research by Li et al. [22] highlights the identification of wild-type isocitrate dehydrogenase 2 (IDH2) as a potential therapeutic target for a particularly aggressive subset of breast cancer known as triple-negative breast cancer (TNBC). This evidence concerns the gene IDH2 and triple-negative breast carcinoma.